Analyzing Mainz Biomed (NASDAQ:MYNZ) and CAE (NYSE:CAE)

CAE (NYSE:CAE) and Mainz Biomed (NASDAQ:MYNZ) are both industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.

Profitability

This table compares CAE and Mainz Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CAE	6.36%	7.45%	3.51%
Mainz Biomed	N/A	N/A	N/A

Risk & Volatility

CAE has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.

Earnings & Valuation

This table compares CAE and Mainz Biomed”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAE	$4.99 billion	1.71	$226.62 million	$0.65	40.98
Mainz Biomed	$659,935.00	11.53	-$21.65 million	($65.60)	-0.01

CAE has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than CAE, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for CAE and Mainz Biomed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAE	1	3	7	0	2.55
Mainz Biomed	1	1	0	0	1.50

CAE presently has a consensus target price of $33.33, indicating a potential upside of 25.14%. Given CAE’s stronger consensus rating and higher possible upside, research analysts clearly believe CAE is more favorable than Mainz Biomed.

Insider and Institutional Ownership

67.4% of CAE shares are held by institutional investors. 18.3% of CAE shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

CAE beats Mainz Biomed on 13 of the 14 factors compared between the two stocks.

About CAE

CAE Inc., together with its subsidiaries, provides simulation training and critical operations support solutions in Canada, the United States, the United Kingdom, Europe, Asia, the Oceania, Africa, and Rest of the Americas. It operates through two segments, Civil Aviation; and Defense and Security. The Civil Aviation segment offers training solutions for flight, cabin, maintenance, and ground personnel in commercial, business, and helicopter aviation; a range of flight simulation training devices; and ab initio pilot training and crew sourcing services, as well as aircraft flight operations solutions. The Defense and Security segment operates as a training and simulation provider that delivers platform-independent solutions to enable and enhance force readiness and security for defense forces, original equipment manufacturers (OEMs), government agencies, and public safety organizations. The company was formerly known as CAE Industries Ltd. and changed its name to CAE Inc. in 1993. CAE Inc. was incorporated in 1947 and is headquartered in Saint-Laurent, Canada.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.